Regulation of catecholamine production from the Adrenal Medulla

Adrenal Glands: From Pathophysiology to Clinical Evidence

Volumn , Issue , 2015, Pages 53-70

  Lymperopoulos, Anastasios ^a   Chowdhary, Smit ^a   Sankar, Kamarena ^a   Simon, Isis ^a  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

Adrenal medulla; Catecholamines; Chromaffin cells; Regulation of hormone secretion; Sympathetic nervous system

Indexed keywords

EID: 85016785897     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (110)

1. Carney JA. Adrenal gland. In: Sternberg SS (ed) Histology for pathologists. Lippincott-Raven, Philadelphia, 1997;pp. 1107-31.
2. Hervonen A, Hervonen H, Rechardt L. Axonal growth from the primitive sympathetic elements of human fetal adrenal medulla. Experientia. 1972; 28: 178-79.
3. Hervonen A, Kanerva L. Neuronal Differentiation in Human Fetal Adrenal Medulla. International Journal of Neuroscience. 1973; 5: 43-46.
4. Symington T. Functional pathology of the human adrenal gland. Williams & Wilkins, Baltimore. 1996.
5. Cryer PE. Physiology and pathophysiology of the human sympathoadrenal neuroendocrine system. The New England journal of medicine. 1980; 303: 436-44.
6. Takiyyuddin MA, Brown MR, Dinh TQ, Cervenka JH, Braun SD, Parmer RJ, Kennedy B, O’Connor DT. Sympatho-adrenal secretion in humans: factors governing catecholamine and storage vesicle peptide co-release. Journal of autonomic pharmacology. 1994; 14: 187-200.
7. Perez-Alvarez A, Albillos A. Key role of the nicotinic receptor in neurotransmitter exocytosis in human chromaffin cells. Journal of neurochemistry. 2007; 103: 2281-90.
8. Tischler AS, DeLellis RA, Slayton VW, Blount MW, Wolfe HJ. Enkephalin-like immunoreactivity in human adrenal medullary cultures. Laboratory investigation;. a journal of technical methods and pathology. 1983; 48: 13-18.
9. O’Connor DT, Frigon RP, Sokoloff RL. Human chromogranin A. Purification and characterization from catecholamine storage vesicles of human pheochromocytoma. Hypertension. 1984; 6: 2-12.
10. Cavadas C, Silva AP, Mosimann F, Cotrim MD, Ribeiro CA, Brunner HR, Grouzmann E. NPY regulates catecholamine secretion from human adrenal chromaffin cells. The Journal of clinical endocrinology and metabolism. 2001; 86: 5956-63.
11. Takiyyuddin MA, Cervenka JH, Sullivan PA, Pandian MR, Parmer RJ, Barbosa JA, O’Connor DT. Is physiologic sympathoadrenal catecholamine release exocytotic in humans?. Circulation. 1990; 81: 185-95.
12. Von Euler U, Franksson C, Hellstrom J. Adrenaline and noradrenaline content of surgically removed human suprarenal glands. Acta physiologica Scandinavica. 1954; 31: 6-8.
13. Perez-Alvarez A, Hernandez-Vivanco A, Cano-Abad M, Albillos A. Pharmacological and biophysical properties of Ca2+ channels and subtype distributions in human adrenal chromaffin cells. Pflugers Archiv:. European journal of physiology. 2008; 456: 1149-62.
14. Cavadas C, Grand D, Mosimann F, Cotrim MD, Fontes Ribeiro CA, Brunner HR, Grouzmann E. Angiotensin II mediates catecholamine and neuropeptide Y secretion in human adrenal chromaffin cells through the AT1 receptor. Regulatory peptides. 2003; 111: 61-5.
15. Rosmaninho-Salgado J, Araujo IM, Alvaro AR, Mendes AF, Ferreira L, Grouzmann E, Mota A, Duarte EP, Cavadas C. Regulation of catecholamine release and tyrosine hydroxylase in human adrenal chromaffin cells by interleukin-1beta: role of neuropeptide Y and nitric oxide. Journal of neurochemistry. 2009; 109: 911-22.
16. Erickson JD, Schafer MK, Bonner TI, Eiden LE, Weihe E. Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proceedings of the National Academy of Sciences of the United States of America. 1996; 93: 5166-5171.
17. Surratt CK, Persico AM, Yang XD, Edgar SR, Bird GS, Hawkins AL, Griffin CA, Li X, Jabs EW, Uhl GR. A human synaptic vesicle monoamine transporter cDNA predicts posttranslational modifications, reveals chromosome 10 gene localization and identifies TaqI RFLPs. FEBS letters. 1993; 318: 325-30.
18. Hagn C, Schmid KW, Fischer-Colbrie R, Winkler H. Chromogranin A, B, and C in human adrenal medulla and endocrine tissues. Laboratory investigation;. a journal of technical methods and pathology. 1986; 55: 405-11.
19. Takiyyuddin MA, Cervenka JH, Pandian MR, Stuenkel CA, Neumann HP, O’Connor DT. Neuroendocrine sources of chromogranin-A in normal man: clues from selective stimulation of endocrine glands. The Journal of clinical endocrinology and metabolism. 1990; 71: 360-9.
20. Boarder MR, Marriott D, Adams M. Stimulus secretion coupling in cultured chromaffin cells. Dependency on external sodium and on dihydropyridine-sensitive calcium channels. Biochemical pharmacology. 1987; 36: 163-7.
21. Chapman ER. How does synaptotagmin trigger neurotransmitter release?. Annual review of biochemistry. 2008; 77: 615-41.
22. Schonn JS, Maximov A, Lao Y, Sudhof TC, Sorensen JB. Synaptotagmin-1 and -7 are functionally overlapping Ca2+ sensors for exocytosis in adrenal chromaffin cells. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105: 3998-4003.
23. de Wit H, Walter Walter AM, Milosevic I, Gulyas-Kovacs A, Riedel D, Sorensen JB, Verhage M. Synaptotagmin-1 docks secretory vesicles to syntaxin-1/SNAP-25 acceptor complexes. Cell. 2009; 138: 935-46.
24. Lymperopoulos A, Garcia D, Walklett K. Pharmacogenetics of cardiac inotropy. Pharmacogenomics. 2014; 15: 1807-21.
25. Albillos A, Gandia L, Michelena P, Gilabert JA, del Valle M, Carbone E, Garcia AG. The mechanism of calcium channel facilitation in bovine chromaffin cells. J Physiol. 1996; 494: 687-95.
26. Currie KP, Fox AP. ATP serves as a negative feedback inhibitor of voltage-gated Ca2+ channel currents in cultured bovine adrenal chromaffin cells. Neuron. 1996; 16: 1027-36.
27. Harkins AB, Fox AP. Activation of purinergic receptors by ATP inhibits secretion in bovine adrenal chromaffin cells. Brain research. 2000; 885: 231-9.
28. Powell AD, Teschemacher AG, Seward EP. P2Y purinoceptors inhibit exocytosis in adrenal chromaffin cells via modulation of voltage-operated calcium channels. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2000; 20: 606-16.
29. Ulate G, Scott SR, Gonzalez J, Gilabert JA, Artalejo AR. Extracellular ATP regulates exocytosis in inhibiting multiple Ca(2+) channel types in bovine chromaffin cells. Pflugers Archiv: European journal of physiology. 2000; 439: 304-14.
30. Brede M, Nagy G, Philipp M, Sorensen JB, Lohse MJ, Hein L. Differential control of adrenal and sympathetic catecholamine release by alpha 2-adrenoceptor subtypes. Molecular endocrinology (Baltimore, Md). 2003; 17: 1640-6.
31. Artalejo CR, Ariano MA, Perlman RL, Fox AP. Activation of facilitation calcium channels in chromaffin cells by D1 dopamine receptors through a cAMP/protein kinase A-dependent mechanism. Nature. 1990; 348: 239-42.
32. Carabelli V, Giancippoli A, Baldelli P, Carbone E, Artalejo AR. Distinct potentiation of L-type currents and secretion by cAMP in rat chromaffin cells. Biophysical journal. 2003; 85: 1326-37.
33. Nagy G, Reim K, Matti U, Brose N, Binz T, Rettig J, Neher E, Sorensen JB. Regulation of releasable vesicle pool sizes by protein kinase A-dependent phosphorylation of SNAP-25. Neuron. 2004; 41: 417-29.
34. Villanueva M, Wightman RM. Facilitation of quantal release induced by a D1-like receptor on bovine chromaffin cells. Biochemistry. 2007; 46: 3881-7.
35. Bauer CS, Woolley RJ, Teschemacher AG, Seward EP. Potentiation of exocytosis by phospholipase C-coupled G-protein-coupled receptors requires the priming protein Munc13-1. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2007; 27: 212-19.
36. Chen XK, Wang LC, Zhou Y, Cai Q, Prakriya M, Duan KL, Sheng ZH, Lingle C, Zhou Z. Activation of GPCRs modulates quantal size in chromaffin cells through G(betagamma) and PKC. Nature neuroscience. 2005; 8: 1160-8.
37. Yoon EJ, Hamm HE, Currie KP. G protein betagamma subunits modulate the number and nature of exocytotic fusion events in adrenal chromaffin cells independent of calcium entry. Journal of neurophysiology. 2008; 100: 2929-39.
38. Jarvis SE, Barr W, Feng ZP, Hamid J, Zamponi GW. Molecular determinants of syntaxin 1 modulation of N-type calcium channels. The Journal of biological chemistry. 2002; 277: 44399-407.
39. Blackmer T, Larsen EC, Bartleson C, Kowalchyk JA, Yoon EJ, Preininger AM, Alford S, Hamm HE, Martin TF er AM, Alford S, Hamm HE, Martin TF. G protein betagamma directly regulates SNARE protein fusion machinery for secretory granule exocytosis. Nature neuroscience. 2005; 8: 421-5.
40. Yoon EJ, Gerachshenko T, Spiegelberg BD, Alford S, Hamm HE. Gbetagamma interferes with Ca2+-dependent binding of synaptotagmin to the soluble Nethylmaleimide- sensitive factor attachment protein receptor (SNARE) complex. Molecular pharmacology. 2007; 72: 1210-9.
41. Tatemoto K, Carlquist M, Mutt V. Neuropeptide Y--a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature. 1982; 296: 659-60.
42. Zukowska Z, Pons J, Lee EW, Li L. Neuropeptide Y: a new mediator linking sympathetic nerves, blood vessels and immune system?. Can J Physiol Pharmacol. 2003; 81: 89-94.
43. Hansel DE, Eipper BA, Ronnett GV. Neuropeptide Y functions as a neuroproliferative factor. Nature. 2001; 410: 940-4.
44. Pons J, Kitlinska J, Ji H, Lee EW, Zukowska Z. Mitogenic actions of neuropeptide Y in vascular smooth muscle cells: synergetic interactions with the beta-adrenergic system. Can J Physiol Pharmacol. 2003; 81: 177-85.
45. Allen JM, Adrian TE, Polak JM, Bloom SR. Neuropeptide Y (NPY) in the adrenal gland. J Auton Nerv Syst. 1983; 9: 559-63.
46. de Quidt ME, Emson PC. Neuropeptide Y in the adrenal gland: characterization, distribution and drug effects. Neuroscience. 1986; 19: 1011-22.
47. Edvinsson L, Emson P, McCulloch J, Tatemoto K, Uddman R. Neuropeptide Y: cerebrovascular innervation and vasomotor effects in the cat. Neurosci Lett. 1983; 43: 79-84.
48. Korner M, Waser B, Reubi JC. High expression of neuropeptide y receptors in tumors of the human adrenal gland and extra-adrenal paraganglia. Clin Cancer Res. 2004; 10: 8426-33.
49. Spinazzi R, Andreis PG, Nussdorfer GG. Neuropeptide-Y and Y-receptors in the autocrine-paracrine regulation of adrenal gland under physiological and pathophysiological conditions (Review). Int J Mol Med. 2005; 15: 3-13.
50. Cavadas C, Cefai D, Rosmaninho-Salgado J, Vieira-Coelho MA, Moura E, Busso N, Pedrazzini T, Grand D, Rotman S, Waeber B, Aubert JF, Grouzmann E. Deletion of the neuropeptide Y (NPY) Y1 receptor gene reveals a regulatory role of NPY on catecholamine synthesis and secretion. Proc Natl Acad Sci U S A. 2006; 103: 10497-502.
51. Hexum TD, Russett LR. Stimulation of cholinergic receptor mediated secretion from the bovine adrenal medulla by neuropeptide Y. Neuropeptides. 1989; 13: 35-41.
52. Shimoda K, Shen GH, Pfeiffer RF, McComb RD, Yang HY. Antiserum against neuropeptide Y enhances the nicotine-mediated release of catecholamines from cultured rat adrenal chromaffin cells. Neurochem Int. 1993; 23: 71-7.
53. Hong M, Li S, Fournier A, St-Pierre S, Pelletier G. Role of neuropeptide Y in the regulation of tyrosine hydroxylase gene expression in rat adrenal glands. Neuroendocrinology. 1995; 61: 85-8.
54. Luke TM, Hexum TD. Tyrosine hydroxylase phosphorylation increases in response to ATP and neuropeptide Y co-stimulation of ERK2 phosphorylation. Pharmacol Res. 2008; 58: 52-7.
55. Thouennon E, Pierre A, Tanguy Y, Guillemot J, Manecka DL, Guerin M, Ouafik L, Muresan M, Klein M, Bertherat J, Lefebvre H, Plouin PF, Yon L, Anouar Y. Expression of trophic amidated peptides and their receptors in benign and malignant pheochromocytomas: high expression of adrenomedullin RDC1 receptor and implication in tumoral cell survival. Endocr Relat Cancer. 2010; 17: 637-51.
56. Vaudry D, Falluel-Morel A, Bourgault S, Basille M, Burel D, Wurtz O, Fournier A, Chow BK, Hashimoto H, Galas L, Vaudry H. Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev. 2009; 61: 283-357.
57. Nielsen HS, Hannibal J, Fahrenkrug J. Prenatal expression of pituitary adenylate cyclase activating polypeptide (PACAP) in autonomic and sensory ganglia and spinal cord of rat embryos. Ann N Y Acad Sci. 1998; 865: 533-6.
58. Breault L, Yon L, Montero M, Chouinard L, Contesse V, Delarue C, Fournier A, Lehoux JG, Vaudry H, Gallo-Payet N. Occurrence and effect of PACAP in the human fetal adrenal gland. Ann N Y Acad Sci. 2000; 921: 429-33.
59. Lamouche S, Yamaguchi N. PACAP release from the canine adrenal gland in vivo: its functional role in severe hypotension. Am J Physiol Regul Integr Comp Physiol. 2003; 284: R588-97.
60. Payet MD, Bilodeau L, Breault L, Fournier A, Yon L, Vaudry H, Gallo-Payet N. PAC1 receptor activation by PACAP-38 mediates Ca2+ release from a cAMP-dependent pool in human fetal adrenal gland chromaffin cells. J Biol Chem. 2003; 278: 1663-70.
61. Isobe K, Kaneko M, Kaneko S, Nissato S, Nanmoku T, Takekoshi K, Okuda Y, Kawakami Y. Expression of mRNAs for PACAP and its receptor in human neuroblastomas and their relationship to catecholamine synthesis. Regul Pept. 2004; 123: 29-32.
62. Tonshoff C, Hemmick L, Evinger MJ. Pituitary adenylate cyclase activating polypeptide (PACAP) regulates expression of catecholamine biosynthetic enzyme genes in bovine adrenal chromaffin cells. J Mol Neurosci. 1997; 9: 127-40.
63. McKenzie S, Marley PD. Caffeine stimulates Ca(2+) entry through store-operated channels to activate tyrosine hydroxylase in bovine chromaffin cells. Eur J Neurosci. 2002; 15: 1485-92.
64. Hamelink C, Tjurmina O, Damadzic R, Young WS, Weihe E, Lee HW, Eiden LE. Pituitary adenylate cyclase-activating polypeptide is a sympathoadrenal neurotransmitter involved in catecholamine regulation and glucohomeostasis. Proc Natl Acad Sci U S A. 2002; 99: 461-6.
65. Grumolato L, Louiset E, Alexandre D, Ait-Ali D, Turquier V, Fournier A, Fasolo A, Vaudry H, Anouar Y. PACAP and NGF regulate common and distinct traits of the sympathoadrenal lineage: effects on electrical properties, gene markers and transcription factors in differentiating PC12 cells. Eur J Neurosci. 2003; 17: 71-82.
66. Takahashi K, Totsune K, Murakami O, Sone M, Itoi K, Miura Y, Mouri T. Pituitary adenylate cyclase activating polypeptide (PACAP)-like immunoreactivity in pheochromocytomas. Peptides. 1993; 14: 365-9.
67. Harmar AJ, Sheward WJ, Morrison CF, Waser B, Gugger M, Reubi JC. Distribution of the VPAC2 receptor in peripheral tissues of the mouse. Endocrinology. 2004; 145: 1203-10.
68. Yon L, Breault L, Contesse V, Bellancourt G, Delarue C, Fournier A, Lehoux JG, Vaudry H, Gallo-Payet N. Localization, characterization, and second messenger coupling of pituitary adenylate cyclase-activating polypeptide receptors in the fetal human adrenal gland during the second trimester of gestation. J Clin Endocrinol Metab. 1998; 83: 1299-305.
69. Ghzili H, Grumolato L, Thouennon E, Tanguy Y, Turquier V, Vaudry H, Anouar Y. Role of PACAP in the physiology and pathology of the sympathoadrenal system. Front Neuroendocrinol. 2008; 29: 128-41.
70. Shimosawa T, Fujita T. Adrenomedullin and its related peptide. Endocr J. 2005; 52: 1-10.
71. Kobayashi H, Yamamoto R, Kitamura K, Kuwasako K, Minami S, Yanagita T, Shiraishi S, Yokoo H, Eto T, Wada A. Selective inhibition of nicotinic cholinergic receptors by proadrenomedullin N-terminal 12 peptide in bovine adrenal chromaffin cells. Brain Res Mol Brain Res. 2001; 87: 175-83.
72. Kobayashi H, Yanagita T, Yokoo H, Wada A. Pathophysiological function of adrenomedullin and proadrenomedullin N-terminal peptides in adrenal chromaffin cells. Hypertens Res. 2003; 26 Suppl: S71-8.
73. Kobayashi H, Yanagita T, Yokoo H, Wada A. Adrenomedullin and proadrenomedullin N-terminal 20 peptide (PAMP) in adrenal chromaffin cells. Peptides. 2001; 22: 1895-901.
74. Renshaw D, Thomson LM, Michael GJ, Carroll M, Kapas S, Hinson JP. Adrenomedullin receptor is found exclusively in noradrenaline-secreting cells of the rat adrenal medulla. J Neurochem. 2000; 74: 1766-72.
75. Mazzocchi G, Albertin G, Andreis PG, Neri G, Malendowicz LK, Champion HC, Bahcelioglu M, Kadowitz PJ, Nussdorfer GG. Distribution, functional role, and signaling mechanism of adrenomedullin receptors in the rat adrenal gland. Peptides. 1999; 20: 1479-87.
76. Masada K, Nagayama T, Hosokawa A, Yoshida M, Suzuki-Kusaba M, Hisa H, Kimura T, Satoh S. Effects of adrenomedullin and PAMP on adrenal catecholamine release in dogs. Am J Physiol. 1999; 276: R1118-24.
77. Thouennon E, Pierre A, Yon L, Anouar Y. Expression of trophic peptides and their receptors in chromaffin cells and pheochromocytoma. Cell Mol Neurobiol. 2010; 30: 1383-9.
78. Lymperopoulos A, Rengo G, Koch WJ. Adrenal adrenoceptors in heart failure: finetuning cardiac stimulation. Trends Mol Med. 2007; 13: 503-11.
79. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984; 311: 819-23.
80. Kaye DM, Lefkovits J, Jennings GL, Bergin P, Broughton A, Esler MD. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol. 1995; 26: 1257-63.
81. Lymperopoulos A, Rengo G, Koch WJ. Adrenergic nervous system in heart failure: pathophysiology and therapy. Circ Res. 2013; 113: 739-53.
82. Siryk-bathgate A, Dabul S, Lymperopoulos A. Current and future G protein-coupled receptor signaling targets for heart failure therapy. Drug Des Devel Ther. 2013; 7: 1209-22.
83. Lymperopoulos A. Physiology and pharmacology of the cardiovascular adrenergic system. Front Physiol. 2013; 4: 240.
84. Lymperopoulos A, Bathgate A. Arrestins in the cardiovascular system. Prog Mol Biol Transl Sci. 2013; 118: 297-334.
85. Lymperopoulos A, Bathgate A. Pharmacogenomics of the heptahelical receptor regulators G-protein-coupled receptor kinases and arrestins: the known and the unknown. Pharmacogenomics. 2012; 13: 323-41.
86. Lymperopoulos A. GRK2 and β-arrestins in cardiovascular disease: Something old, something new. Am J Cardiovasc Dis. 2011; 1: 126-37.
87. Taraviras S, Olli-lähdesmäki T, Lymperopoulos A, Charitonidou D, Mavroidis M, Kallio J, Scheinin M, Flordellis C. Subtype-specific neuronal differentiation of PC12 cells transfected with alpha2-adrenergic receptors. Eur J Cell Biol. 2002; 81: 363-74.
88. Lymperopoulos A, Rengo G, Funakoshi H, Eckhart AD, Koch WJ. Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure. Nat Med. 2007; 13: 315-23.
89. Berkowitz DE, Price DT, Bello EA, Page SO, Schwinn DA. Localization of messenger RNA for three distinct alpha 2-adrenergic receptor subtypes in human tissues. Evidence for species heterogeneity and implications for human pharmacology. Anesthesiology. 1994; 81: 1235-44.
90. Link, R.E., Desai, K., Hein, L., Stevens, M.E., Chruscinski, A., Bernstein, D., Barsh GS, Kobilka BK. Cardiovascular regulation in mice lacking alpha2-adrenergic receptor subtypes b and c. Science. 1996; 273: 803-5.
91. Lymperopoulos A, Karkoulias G, Koch WJ, Flordellis CS. Alpha2-adrenergic receptor subtype-specific activation of NF-kappaB in PC12 cells. Neurosci Lett. 2006; 402: 210-5.
92. Karkoulias G, Mastrogianni O, Lymperopoulos A, Paris H, Flordellis C. Alpha(2)-Adrenergic receptors activate MAPK and Akt through a pathway involving arachidonic acid metabolism by cytochrome P450-dependent epoxygenase, matrix metalloproteinase activation and subtype-specific transactivation of EGFR. Cell Signal. 2006; 18: 729-39.
93. Karkoulias G, Mastrogianni O, Ilias I, Lymperopoulos A, Taraviras S, Tsopanoglou N, Sitaras N, Flordellis CS. Alpha 2-adrenergic receptors decrease DNA replication and cell proliferation and induce neurite outgrowth in transfected rat pheochromocytoma cells. Ann N Y Acad Sci. 2006; 1088: 335-45.
94. Small KM, Brown KM, Forbes SL, Liggett SB: Polymorphic deletion of three intracellular acidic residues of the alpha 2B-adrenergic receptor decreases G proteincoupled receptor kinase-mediated phosphorylation and desensitization. J Biol Chem 2001; 276: 4917-22.
95. Nguyen K, Kassimatis T, Lymperopoulos A. Impaired desensitization of a human polymorphic α2B-adrenergic receptor variant enhances its sympatho-inhibitory activity in chromaffin cells. Cell Commun Signal. 2011; 9: 5.
96. Foucart S, De champlain J, Nadeau R. In vivo interactions between prejunctional alpha 2- and beta 2-adrenoceptors at the level of the adrenal medulla. Can J Physiol Pharmacol. 1988; 66: 1340-3.
97. Cortez V, Santana M, Marques AP, Mota A, Rosmaninho-salgado J, Cavadas C. Regulation of catecholamine release in human adrenal chromaffin cells by β- adrenoceptors. Neurochem Int. 2012; 60: 387-93.
98. Zaika OL, Pochynyuk OM, Kostyuk PG, Yavorskaya EN, Lukyanetz EA. Acetylcholine-induced calcium signalling in adrenaline- and noradrenaline-containing adrenal chromaffin cells. Arch Biochem Biophys. 2004; 424: 23-32.
99. Armando I, Jezova M, Bregonzio C, Baiardi G, Saavedra JM. Angiotensin II AT1 and AT2 receptor types regulate basal and stress-induced adrenomedullary catecholamine production through transcriptional regulation of tyrosine hydroxylase. Ann N Y Acad Sci. 2004; 1018: 302-9.
100. Wallace DJ, Chen C, Marley PD. Histamine promotes excitability in bovine adrenal chromaffin cells by inhibiting an M-current. J Physiol (Lond). 2002; 540: 921-39.
101. Tseng CJ, Chan JY, Lo WC, Jan CR. Modulation of catecholamine release by endogenous adenosine in the rat adrenal medulla. J Biomed Sci. 2001; 8: 389-94.
102. Lymperopoulos A, Rengo G, Zincarelli C, Soltys S, Koch WJ. Modulation of adrenal catecholamine secretion by in vivo gene transfer and manipulation of G protein-coupled receptor kinase-2 activity. Mol Ther. 2008; 16: 302-7.
103. Schneider J, Lother A, Hein L, Gilsbach R. Chronic cardiac pressure overload induces adrenal medulla hypertrophy and increased catecholamine synthesis. Basic Res Cardiol. 2011; 106: 591-602.
104. Lymperopoulos A, Rengo G, Gao E, Ebert SN, Dorn GW, Koch WJ. Reduction of sympathetic activity via adrenal-targeted GRK2 gene deletion attenuates heart failure progression and improves cardiac function after myocardial infarction. J Biol Chem. 2010; 285: 16378-86.
105. Lymperopoulos A, Rengo G, Gao E, Ebert SN, Dorn GW, Koch WJ. Reduction of sympathetic activity via adrenal-targeted GRK2 gene deletion attenuates heart failure progression and improves cardiac function after myocardial infarction. J Biol Chem. 2010; 285: 16378-86.
106. Rengo G, Lymperopoulos A, Zincarelli C, Femminella G, Liccardo D, Pagano G, de Lucia C, Cannavo A, Gargiulo P, Ferrara N, Perrone Filardi P, Koch W, Leosco D. Blockade of β-adrenoceptors restores the GRK2-mediated adrenal α(2) -adrenoceptorcatecholamine production axis in heart failure. Br J Pharmacol. 2012; 166: 2430-40.
107. Womble JR, Larson DF, Copeland JG, Brown BR, Haddox MK, Russell DH. Adrenal medulla denervation prevents stress-induced epinephrine plasma elevation and cardiac hypertrophy. Life Sci. 1980; 27: 2417-20.
108. Lymperopoulos A, Rengo G, Zincarelli C, Kim J, Soltys S, Koch WJ. An adrenal betaarrestin 1-mediated signaling pathway underlies angiotensin II-induced aldosterone production in vitro and in vivo. Proc Natl Acad Sci USA. 2009; 106: 5825-30.
109. Lymperopoulos A, Rengo G, Zincarelli C, Kim J, Koch WJ. Adrenal beta-arrestin 1 inhibition in vivo attenuates post-myocardial infarction progression to heart failure and adverse remodeling via reduction of circulating aldosterone levels. J Am Coll Cardiol. 2011; 57: 356-65.
110. Bathgate-siryk A, Dabul S, Pandya K, Walklett K, Rengo G, Cannavo A, De Lucia C, Liccardo D, Gao E, Leosco D, Koch WJ, Lymperopoulos A. Negative impact of β- arrestin-1 on post-myocardial infarction heart failure via cardiac and adrenal-dependent neurohormonal mechanisms. Hypertension. 2014; 63: 404-12.